Wednesday, August 27th, 2025
Stock Profile: ANAB
ANAB Logo

AnaptysBio, Inc. (ANAB)

Market: NASD | Currency: USD

Address: 10770 Wateridge Circle

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in Show more




📈 AnaptysBio, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for AnaptysBio, Inc.


DateReported EPS
2025-11-05 (estimated upcoming)-
2025-08-06-1.34
2025-05-05-1.28
2025-02-27-0.72
2024-11-05-1.14
2024-08-05-1.71
2024-05-09-1.64
2024-03-11-1.59
2023-11-02-1.41
2023-08-07-1.5
2023-05-11-1.58
2023-03-01-0.93
2022-11-08-1.18
2022-08-08-1.15
2022-05-04-1.31
2022-03-07-1.18
2021-11-04-0.24
2021-08-09-0.02
2021-05-04-0.66
2021-02-251.2
2020-11-04-0.87
2020-08-10-0.79
2020-05-06-0.3
2020-03-02-0.75
2019-11-08-1.15




📰 Related News & Research


No related articles found for "anaptysbio inc".